SpringerLink
Log in

Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study

  • Letter to the Editor
  • Published:
Bone Marrow Transplantation Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fagan TJ . Nomogram for Baye’s Theorem. N Engl J Med 1975; 293: 257.

    CAS  Google Scholar 

  2. Griner PF, Mayewski RJ, Mushlin AI, Greenland P . Selection and interpretation of diagnostic tests and procedures. Ann Intern Med 1981; 94: 557–592.

    CAS  PubMed  Google Scholar 

  3. Marr KA, Leisenring W . Design issues in studies evaluating diagnostic tests for Aspergillosis. Clin Infect Dis 2005; 41 (suppl): S381–S386.

    Article  Google Scholar 

  4. Donnelly JP, Leeflang MM . Galactomannan detection and diagnosis of invasive Aspergillosis. Clin Infect Dis 2010; 50: 1070–1071.

    Article  Google Scholar 

  5. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ et al. Posaconazole vs Itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348–359.

    Article  CAS  Google Scholar 

  6. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335–347.

    Article  CAS  Google Scholar 

  7. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471–5489.

    Article  CAS  Google Scholar 

  8. Sánchez-Ortega I, Patiño B, Arnan M, Peralta T, Parody R, Gudiol C et al. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole vs itraconazole in allogeneic blood and marrow transplantation. Bone Marrow Transplant 2011; 46: 733–739.

    Article  Google Scholar 

  9. Duarte RF, Sánchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A et al. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59: 1696–1702.

    Article  CAS  Google Scholar 

  10. Cornely OA . Galactomannan testing during mold-active prophylaxis. Clin Infect Dis 2014; 59: 1703–1704.

    Article  CAS  Google Scholar 

  11. De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821.

    Article  Google Scholar 

  12. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005; 41: 1242–1250.

    Article  CAS  Google Scholar 

  13. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis 2009; 48: 1042–1051.

    Article  CAS  Google Scholar 

  14. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol 2010; 28: 667–674.

    Article  Google Scholar 

  15. Aguado JM, Vázquez L, Fernández-Ruiz M, Villaescusa T, Ruiz-Camps I, Barba P et al. Serum galactomannan versus a combination of galactomannan and polymerase chain reaction-based Aspergillus DNA detection for early therapy of invasive Aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015; 60: 405–414.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was partly supported by an unrestricted research grant from Schering Plough.

Author contributions

RFD, ISO and MCE are responsible for the conception and design of the study and wrote the initial draft of this manuscript. All authors contributed to the execution of the study, the analysis and/or interpretation of the data, reviewed the manuscript content and approved the manuscript for publication.

Author information

Author notes

  1. R F Duarte and I Sánchez-Ortega: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, Catalan Institute of Oncology–Hospital Duran i Reynals, Biomedical Research Institute of Bellvitge (Idibell), Barcelona, Spain

    R F Duarte, I Sánchez-Ortega, M Arnan, B Patiño & A Sureda

  2. Department of Microbiology, Hospital Universitario de Bellvitge, Barcelona, Spain

    J Ayats

  3. Department of Micology, Centro Nacional de Microbiología–Instituto de Salud Carlos III, Madrid, Spain

    M Cuenca-Estrella

Authors
  1. R F Duarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Sánchez-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Arnan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B Patiño
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Ayats
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Sureda
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Cuenca-Estrella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R F Duarte.

Ethics declarations

Competing interests

MA, RFD and ISO have received consultation and/or speaker fees from Esteve, Gilead Science, Merck Sharp & Dohme, Pfizer and/or Schering Plough during the study period. MCE has received grant support from Astellas Pharma, bioMerieux, Gilead Sciences, Merck Sharp and Dohme, Pfizer, Schering Plough, Soria Melguizo SA and Ferrer International, has been an advisor/consultant to Astellas Pharma, Gilead Sciences, Merck Sharp and Dohme, Pfizer and Schering Plough, and has received honoraria for talks on behalf of Gilead Sciences, Merck Sharp and Dohme, Pfizer, Astellas Pharma and Schering Plough. The remaining authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Duarte, R., Sánchez-Ortega, I., Arnan, M. et al. Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study. Bone Marrow Transplant 52, 326–329 (2017). https://doi.org/10.1038/bmt.2016.279

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2016.279

  • Springer Nature Limited

Search

Navigation